RxDoctor Payments Data

Lauren Brown, NP

Gerontology · Portland, ORNPI 1346999737

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,644 of the $31,551 with a category attached, or 62.3%. Amylyx Pharmaceuticals, Inc. accounts for 82.6% of it on its own, with 6 other manufacturers making up the rest. Among gerontology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,551in general payments, 2019–2025

Across 64 payments — averaging $492.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amylyx Pharmaceuticals, Inc.$26K
  • Sanofi$5K
  • AbbVie$125
  • Lilly USA, LLC$56
  • Tanabe Pharma America, Inc.$28
  • Biogen$20
  • plus $14 from 1 others

What the payments were for

  • Consulting fees$5,06516%
  • Speaking & faculty fees$19,64462%
  • Travel & lodging$5,49417%
  • Food & beverage$1,3194%
  • Education$280%

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,551 in reported general payments places this provider in the 95th percentile of 53 gerontology providers in Oregon.

See all gerontology providers in Oregon

Medicare billing

Part B allowed, 2024
$42,016
Medicare patients
85
Services billed
2,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone110$1,576,503
RelyvrioSod Phenylbutyrat/Taurursodiol26$318,557
NuedextaDextromethorphan Hbr/Quinidine27$35,408
Emgality PenGalcanezumab-Gnlm39$30,224
Riluzole126$13,267
Aimovig AutoinjectorErenumab-Aooe13$9,449
Naproxen15$4,240
Baclofen56$3,904
Gabapentin34$1,862
Scopolamine16$1,851
Sumatriptan Succinate38$1,721
Mexiletine Hcl13$1,284
Pregabalin31$1,229
Lorazepam57$1,036
Glycopyrrolate19$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amylyx Pharmaceuticals, Inc.Relyvrio$26,062$318,55726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 gerontology providers in Oregon.

Other gerontology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →